In patients with moderate-to-severe plaque psoriasis , the @ mg twice daily dose of tofacitinib was non-inferior to etanercept @ mg twice weekly and was superior to placebo , but the @ mg twice daily dose did not show non-inferiority to etanercept @ mg twice weekly .